Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialRobin Kate Kelley, Ming‐Huang Chen, Chris Verslype et al.|The Lancet|2023Cited by 1k
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studiesYoshiaki Nakamura, Takayuki Yoshino, Hiroya Taniguchi et al.|Nature Medicine|2020Cited by 366
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trialChigusa Morizane, Junji Furuse, Takuji Okusaka et al.|Annals of Oncology|2019Cited by 333
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 studyMakoto Ueno, Junji Furuse, Masafumi Ikeda et al.|The Lancet. Gastroenterology & hepatology|2019Cited by 331
Chemotherapy for hepatocellular carcinoma: current status and future perspectivesMasafumi Ikeda, Junji Furuse, Chigusa Morizane et al.|Japanese Journal of Clinical Oncology|2017Cited by 274